Newbridge Financial Services Group, Inc. Sarepta Therapeutics, Inc. Transaction History

Newbridge Financial Services Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Mar 28, 2024	SELL	$67.31 - $124.76 $2,894 - $5,364	-43 Reduced 12.54%	300 $28,000
Q3 2023 Oct 17, 2023	SELL	$102.5 - $123.59 $30,750 - $37,077	-300 Reduced 46.66%	343 $41,000
Q3 2022 Oct 13, 2022	SELL	$75.71 - $119.24 $12,719 - $20,032	-168 Reduced 20.72%	643 $71,000
Q2 2022 Jul 15, 2022	SELL	$62.69 - $88.44 $23,947 - $33,784	-382 Reduced 32.02%	811 $61,000
Q1 2022 Apr 26, 2022	BUY	$63.15 - $90.42 $2,210 - $3,164	35 Added 3.02%	1,193 $93,000
Q4 2021 Jan 19, 2022	SELL	$77.28 - $99.42 $11,592 - $14,913	-150 Reduced 11.47%	1,158 $104,000
Q3 2021 Oct 27, 2021	BUY	$65.97 - $92.48 $3,298 - $4,624	50 Added 3.97%	1,308 $121,000
Q2 2021 Sep 07, 2021	BUY	$69.38 - $86.75 $5,758 - $7,200	83 Added 7.06%	1,258 $98,000
Q1 2021 Sep 07, 2021	BUY	$72.25 - $168.95 $41,543 - $97,146	575 Added 95.83%	1,175 $88,000
Q3 2020 Sep 07, 2021	BUY	$127.12 - $172.34 $76,272 - $103,404	600 New	600 $84,000

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.6B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.